Key Takeaways
- Sharp margin recovery, led by product mix: EBITDA margin jumped 504 bps QoQ to 13.9% as the new anti-diabetic line scaled and ibuprofen pricing firmed, with management targeting a normalized 18-20% in 1-2 quarters.
- Anti-diabetic now the dominant driver: The segment surged to ~41% of revenue on the back of gliptin patent expiries, completely replacing the ARV contribution that collapsed from ~40% to under 1% year-on-year.
- Ibuprofen poised for a multi-market breakout: CEP clearance opens regulated Europe, domestic share is set to rise, and management projects ibuprofen alone at ~25% of FY24 revenue (₹150-200 crores).
- ARV recovery is pure upside: Tender inflows signal a demand pickup; management expects ARV to return to 12-15% of revenue next year, layering incremental operating leverage onto a base already rebuilt without it.
- What to watch next quarter: The pace of ibuprofen’s European sales ramp, whether anti-diabetic momentum sustains as the US patent cliff nears, and any formal FY24 revenue target from the upcoming board meeting.
Profitability Turnaround
- Product mix drove the margin leap: The 504 bps sequential EBITDA margin expansion to 13.9% was powered by the rapid scale-up of the higher-margin anti-diabetic line and a demand uptick in non-ARV products, which together lifted the overall realization profile.
- Normalization target within sight: Management expects EBITDA margins to reach a normalized 18-20% band in the next 1-2 quarters, supported by steady revenue growth and the company’s bounce-back trajectory.
- Inventory drag is fading: Nine-month inventory levels are down 15-20% versus FY2022, with high-cost stock now confined to slow-moving COVID-related products (~10% of cost) that management is evaluating for sale.
- Molnupiravir overhang persists: The status on liquidating molnupiravir inventory remains unchanged from the prior quarter, with no resolution yet on how to move forward.
Potluri: "May be, it might take 1-2 quarters but again as we mentioned, the companies is on the bounce back mode."
Anti-Diabetic: The New Anchor
- Patent expiry unlocked the surge: Sales in the anti-diabetic segment picked up sharply over the last two quarters as patents on molecules like sitagliptin expired, allowing SMS to scale commercial production of multiple salts (phosphate, HCL) and vildagliptin quickly.
- Contribution leap to 41%: The segment now accounts for close to 41% of overall revenue from operations, making it the single largest therapy and the primary engine replacing the lost ARV topline.
- JV partnership de-risks European access: The company has a good partnership with its European JV partner, the only market where the relevant patent has already expired, providing visibility on near-term demand.
- US patent cliff is the next catalyst: The US patent expiry is set for 2024, and linagliptin is already in the pipeline, positioning anti-diabetic to remain the driving force next year.
Potluri: "We are an API Company, definitely based on the current trend we think the anti-diabetic could be the driving force in the next year as well because of the recent expiry on that sitagliptin but it could definitely change."
Ibuprofen: Pricing Floor & Regulatory Catalyst
- Pricing has bottomed out: After several muted quarters, ibuprofen pricing pressures have eased and management believes prices have found a floor, expecting a stable straight line barring external shocks like new entrants or manufacturing disruptions.
- CEP clearance unlocks regulated Europe: The receipt of a CEP for ibuprofen opens access to the current and regulated European market, where sample quantities have already been shipped and products are under registration with different countries.
- Domestic share set to expand: The domestic market is large for ibuprofen, and the company expects its domestic revenue share to rise from 18% to 25-30% going forward, partly driven by this product.
- FY24 revenue projection: Ibuprofen is expected to be a very big contributor in FY24, projected at approximately 25% of total revenue, or ₹150-200 crores.
- Capacity expansion is demand-gated: The Vizag ibuprofen plant can scale to 700 tons per month with a modest ₹10-15 crores CAPEX; expansion will be taken up in the next few quarters and is expected operational by Q3 FY24, scaled based on demand.
- Backward integration to protect margin: The company targets 80-85% backward integration in FY24, manufacturing most ibuprofen raw materials in-house to reduce overseas dependency and control input costs.
Potluri: "We feel that the prices have bottomed out at this point of time and we feel that unless there is a new entrant or someone is having some issues with manufacturing. I think the prices will more or less be the same, unless something is happening in the market so that we keep our eyes open and we are watchful but we cannot predict those at this point of time."
ARV: From Headwind to Tailwind
- ARV demand collapsed, but the hole is filled: ARV contribution fell from ~40% (~₹200 crores) last year to less than 1% this year (4% in the nine-month period), yet the company maintained topline by replacing it entirely with other products, notably anti-diabetic.
- Tender inflows signal a recovery: Demand for ARV products is picking up, with tenders received a few months back, and management sees better visibility on order inflow going forward.
- ARV return is incremental upside: Because the topline has already been rebuilt without ARV, any recovery in this segment will be additional revenue and operating leverage over and above the normalized base.
- Next-year contribution estimate: Management expects ARV to contribute around 12-15% of revenue next year, though it cautions the forecast is uncertain because the business is purely tender-based.
Potluri: "Anti-viral will come back, definitely we will be and that will be additional revenue for the Company."
Portfolio & Operational Strategy
- Therapy mix is deliberately fluid: Management does not target fixed therapeutic shares, adapting instead to market scenarios as an API company; anti-diabetic leads now due to patent expiries, but the mix can shift.
- Intermediates share shrinks by design: Intermediates revenue fell from ~4% to ~1% year-on-year because last year’s contribution came from contract manufacturing that has since wound down.
- Anti-migraine is a steady niche: Topline contribution from anti-migraine is expected to remain in the 14-15% range, with no major patent-expiry products on the horizon that would significantly alter the trajectory given the niche-volume nature of the APIs.
- Capacity utilization has room to run: Overall utilization (excluding ibuprofen) is targeted to reach at least 60% from the current ~40%, providing operating leverage without major CAPEX.
- Consolidation before expansion: Management explicitly wants to consolidate at this point before undertaking another expansion; no greenfield or major capacity addition is planned this financial year beyond the phased ibuprofen scale-up.
- R&D spend to normalize at 3-4%: Steady-state R&D spend is expected to be around 3-4%, possibly a little more, with work underway on enzymatic routes for intermediates at both R&D and scale-up stages.
Potluri: "We want to consolidate at this point of time before going for another expansion."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin normalization | Reach normalized level of 18%-20% | Next 1-2 quarters |
| Ibuprofen Europe sales uptick | See a very good uptick in sales to Europe | Next 4-6 months |
| Ibuprofen capacity expansion | Scale to 700 tons/month (₹10-15 cr CAPEX) | Operational by Q3 FY24 |
| Ibuprofen FY24 revenue contribution | ~25% of total revenue (~₹150-200 crores) | FY24 |
| ARV revenue contribution | Return to 12%-15% of revenue, but not very sure because it is based purely on tenders | Next year (FY24) |
| Backward integration | Achieve 80%-85% in-house raw material manufacturing, currently around 50% | FY24 |
| Domestic revenue share | Increase from 18% to 25%-30% | Going forward |
| Capacity utilization (ex-ibuprofen) | Reach at least 60% from current 40% | No date |
| R&D spend | Steady-state at 3%-4% of revenue | Ongoing |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue from operations (API segment) | ₹146.2 cr, API segment contributed ~98.2% of consolidated revenue |
| 9M FY23 revenue from operations (API segment) | ₹368.7 cr, API segment contributed ~99% of consolidated revenue |
| EBITDA margin | 13.9%, improved 504 bps sequentially |
| Profit after tax | ₹5.3 cr, substantial growth from previous quarter |
| Normalized EBITDA margin target | 18%–20%, expected in the next couple of quarters |
| Revenue growth expectation (not formal target) | 15%–20% on existing revenues, typical range |
| API domestic market share | 15% of API revenue, expected to increase to 25%–30% |
| API export market share | 85% of API revenue |
| Top 3 export geographies contribution | 65%–70% of export revenue, from US, Europe, and Japan |
| Anti-diabetic therapy share of revenue | 41% of total revenue from operations |
| ARV therapy share of revenue | 1% of total sales, down from ~30%–40% last year |
| Anti-migraine therapy share of revenue | 14% of total sales, expected to go up to 15% |
| Ibuprofen current monthly production | 180–200 tons, with installed capacity of 300–400 tons per month |
| Ibuprofen capacity utilization | 60%–70% |
| Overall capacity utilization (ex-ibuprofen) | 40%, target to hit at least 60% |
| R&D spend (9M FY23) | ~3% of revenue, steady-state target 3%–4% |
| CAPEX done so far this year | ₹5–8 cr, for regular environmental and balance equipment |
| Backward integration level | ~50%, target 80%–85% in FY24 |
| Nine-month inventory reduction | 15%–20% lower compared to FY2022 |